WallStSmart

Nice Ltd ADR (NICE)vsZepp Health Corp (ZEPP)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Nice Ltd ADR generates 1038% more annual revenue ($2.95B vs $258.90M). NICE leads profitability with a 20.8% profit margin vs -15.5%. NICE earns a higher WallStSmart Score of 78/100 (B+).

NICE

Strong Buy

78

out of 100

Grade: B+

Growth: 8.0Profit: 7.5Value: 9.3Quality: 7.5
Piotroski: 4/9Altman Z: 3.23

ZEPP

Hold

41

out of 100

Grade: D

Growth: 4.7Profit: 2.0Value: 6.7Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

NICEUndervalued (+45.3%)

Margin of Safety

+45.3%

Fair Value

$202.91

Current Price

$101.87

$101.04 discount

UndervaluedFair: $202.91Overvalued
ZEPPUndervalued (+48.6%)

Margin of Safety

+48.6%

Fair Value

$46.70

Current Price

$17.47

$29.23 discount

UndervaluedFair: $46.70Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

NICE6 strengths · Avg: 9.5/10
P/E RatioValuation
10.5x10/10

Attractively priced relative to earnings

EPS GrowthGrowth
56.7%10/10

Earnings expanding 56.7% YoY

Debt/EquityHealth
0.0210/10

Conservative balance sheet, low leverage

Altman Z-ScoreHealth
3.2310/10

Safe zone — low bankruptcy risk

Profit MarginProfitability
20.8%9/10

Keeps 21 of every $100 in revenue as profit

PEG RatioValuation
0.868/10

Growing faster than its price suggests

ZEPP2 strengths · Avg: 10.0/10
Price/BookValuation
1.3x10/10

Reasonable price relative to book value

Revenue GrowthGrowth
43.0%10/10

Revenue surging 43.0% year-over-year

Areas to Watch

NICE1 concerns · Avg: 2.0/10
Price/BookValuation
39.6x2/10

Trading at 39.6x book value

ZEPP4 concerns · Avg: 2.0/10
Market CapQuality
$247.54M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-17.2%2/10

ROE of -17.2% — below average capital efficiency

EPS GrowthGrowth
-68.1%2/10

Earnings declined 68.1%

Profit MarginProfitability
-15.5%1/10

Currently unprofitable

Comparative Analysis Report

WallStSmart Research

Bull Case : NICE

The strongest argument for NICE centers on P/E Ratio, EPS Growth, Debt/Equity. Profitability is solid with margins at 20.8% and operating margin at 22.4%. PEG of 0.86 suggests the stock is reasonably priced for its growth.

Bull Case : ZEPP

The strongest argument for ZEPP centers on Price/Book, Revenue Growth. Revenue growth of 43.0% demonstrates continued momentum.

Bear Case : NICE

The primary concerns for NICE are Price/Book.

Bear Case : ZEPP

The primary concerns for ZEPP are Market Cap, Return on Equity, EPS Growth.

Key Dynamics to Monitor

NICE profiles as a mature stock while ZEPP is a hypergrowth play — different risk/reward profiles.

ZEPP carries more volatility with a beta of 1.77 — expect wider price swings.

ZEPP is growing revenue faster at 43.0% — sustainability is the question.

Monitor SOFTWARE - APPLICATION industry trends, competitive dynamics, and regulatory changes.

Bottom Line

NICE scores higher overall (78/100 vs 41/100), backed by strong 20.8% margins. ZEPP offers better value entry with a 48.6% margin of safety. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Nice Ltd ADR

TECHNOLOGY · SOFTWARE - APPLICATION · USA

NICE Ltd. provides business software solutions globally. The company is headquartered in Ra'anana, Israel.

Visit Website →

Zepp Health Corp

TECHNOLOGY · CONSUMER ELECTRONICS · China

Zepp Health Corporation, an activity and biometric data-driven company, develops, manufactures and sells smart wearable technology devices in the People's Republic of China. The company is headquartered in Hefei, the People's Republic of China.

Want to dig deeper into these stocks?